Molecular biology reports · 2025
The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrence.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Souza Ariane P, Silva Isabely M, Vacario Beatriz G L, Koike Alexsandro, Paz Rafael G, Coradi Carolina, Wrzesinski Emily M S, Trigo Guilherme L, Simão Andrea N C, Lozovoy Marcell A B, Guembarovski Roberta L, Panis Carolina, Serpeloni Juliana Mara
Аннотация
BACKGROUND: Urothelial bladder cancer (UBC) is the ninth most common cancer worldwide. It is essential to investigate factors that may affect susceptibility and determine the prognosis of UBC. IRF5 is an interferon regulatory factor that modulates cellular differentiation during immune responses and oncogenesis.
METHODS AND RESULTS: The frequency of the rs3757385 (T > G) variant in IRF5 was evaluated in 295 patients with UBC and 295 individuals without neoplasia in a Brazilian population. Nitric oxide metabolites (NOx) systemic levels and IRF5 expression in normal and tumoral bladder tissues were also evaluated, as was the interaction between these parameters and prognostic indicators. Bioinformatics analyses compared gene expression patterns with TCGA data. The polymorphism was not associated with susceptibility to UBC. The mutated allele (G) was associated with a decrease in the relapses in the genotypic (OR = 0.205) and dominant (OR = 0.380) models. Hypertensive individuals with TG (genotypic, OR = 0.079) or TG + GG (dominant model, OR = 0.184) had fewer muscle-invasive tumors. Polymorphism did not alter the plasmatic NOx levels. Higher IRF5 expression was observed in patients with at least one G allele, males, smokers, and alcoholics. Directly, NOx was not associated with the prognostic parameters; however, individuals with the G allele and high NOx levels showed protection against relapses.
CONCLUSION: Our study highlights the association between rs3757385 (G allele) and high plasmatic NOx levels as good prognostic factors in UBC.
METHODS AND RESULTS: The frequency of the rs3757385 (T > G) variant in IRF5 was evaluated in 295 patients with UBC and 295 individuals without neoplasia in a Brazilian population. Nitric oxide metabolites (NOx) systemic levels and IRF5 expression in normal and tumoral bladder tissues were also evaluated, as was the interaction between these parameters and prognostic indicators. Bioinformatics analyses compared gene expression patterns with TCGA data. The polymorphism was not associated with susceptibility to UBC. The mutated allele (G) was associated with a decrease in the relapses in the genotypic (OR = 0.205) and dominant (OR = 0.380) models. Hypertensive individuals with TG (genotypic, OR = 0.079) or TG + GG (dominant model, OR = 0.184) had fewer muscle-invasive tumors. Polymorphism did not alter the plasmatic NOx levels. Higher IRF5 expression was observed in patients with at least one G allele, males, smokers, and alcoholics. Directly, NOx was not associated with the prognostic parameters; however, individuals with the G allele and high NOx levels showed protection against relapses.
CONCLUSION: Our study highlights the association between rs3757385 (G allele) and high plasmatic NOx levels as good prognostic factors in UBC.